Who are Jade Biosciences, Inc.'s main suppliers?

Jade Biosciences, Inc. (JBIO) key suppliers include: PARAGON, WUXI-BIOLOGICS-IRELAND-LIMITED, Climb Bio, Inc., Novartis AG, Takeda Pharmaceutical Company Limited and 4 more. View the full supplier network at chainsifter.com/chain/JBIO.

Who are Jade Biosciences, Inc.'s major customers?

Jade Biosciences, Inc. (JBIO) key customers include: Climb Bio, Inc., Climb Bio, Inc., Novartis AG, Novartis AG, Oruka Therapeutics, Inc. and 13 more. View the full customer network at chainsifter.com/chain/JBIO.

What sector is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Jade Biosciences, Inc. Suppliers, Customers & Supply Chain (JBIO)

9Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Jade Biosciences, Inc. (JBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

31Total relationships

2Distinct source URLs

6High confidence

0.756Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Jade Biosciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
PARAGON	PARAGON	92%	Paragon granted the Company a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and otherwise exploit certain antibodies and products targeting BAFF-R…
WUXI-BIOLOGICS-IRELAND-LIMITED	WUXI-BIOLOGICS-IRELAND-LIMITED	92%	Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics Ireland's patent rights, know-how, cell line, biological mat…
CLYM	Climb Bio, Inc.	72%	Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product ca…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSE…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TKPH…
TVTX	Travere Therapeutics, Inc.	72%	Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TVTX g…
VERA	Vera Therapeutics, Inc.	72%	Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA g…
VOR	Vor Biopharma Inc.	72%	Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR grap…
VRTX	Vertex Pharmaceuticals Incorporated	72%	Reciprocal relationship from VRTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VRTX g…

Jade Biosciences, Inc. Customers

Ticker	Name	Confidence	Evidence
CLYM	Climb Bio, Inc.	72%	Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subst…
CLYM	Climb Bio, Inc.	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
NVSEF	Novartis AG	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSE…
ORKA	Oruka Therapeutics, Inc.	72%	Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA g…
ORKA	Oruka Therapeutics, Inc.	72%	are negotiating agreements with the federal government regarding most favored nation pricing and onshoring of production and research and development. Any direct tariffs, if imposed on pharmaceutical…
SNYNF	Sanofi	72%	property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. Further, we may be required to protect our future patents, i…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from SNYN…
TKPHF	Takeda Pharmaceutical Company Limited	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quar…
TVTX	Travere Therapeutics, Inc.	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
TVTX	Travere Therapeutics, Inc.	72%	Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TVTX g…
VERA	Vera Therapeutics, Inc.	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
VERA	Vera Therapeutics, Inc.	72%	Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subst…
VOR	Vor Biopharma Inc.	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…
VOR	Vor Biopharma Inc.	72%	Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR grap…
VRTX	Vertex Pharmaceuticals Incorporated	72%	Reciprocal relationship from VRTX graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subst…
VRTX	Vertex Pharmaceuticals Incorporated	72%	fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr…

Jade Biosciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
JBIO-DEBT-14390	Warrants outstanding: 11143000	90%	xbrl warrant detail from xbrl 2025-12-31.
JBIO-DEBT	Debt stack $849,000	90%	Market cache reports total debt of $849,000.
JBIO-DEBT-10422	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Jade Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Jade Biosciences, Inc..

Jade Biosciences, Inc. Ownership

Holder	Name	Confidence	Evidence
JBIO-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 122 tracked holders.

Jade Biosciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
DSGN	Design Therapeutics, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
AUPH	Aurinia Pharmaceuticals Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
AZN	AstraZeneca PLC	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CSLLY	CSL Limited	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	1	['customer', 'supplier']
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2

Jade Biosciences, Inc. Supply Chain